Bioequivalence services for generic and innovative drugs
Bioequivalence is a cornerstone in modern drug development and regulatory approval
Bioequivalence services
For pharmaceutical companies developing generic drugs, demonstrating bioequivalence is not just a regulatory requirement – it is a critical step in proving that a generic product performs in the same way as its branded counterpart. At Particle Analytical, we provide bioequivalence services that ensure compliance with FDA and EMA guidelines, reduce regulatory risk, and accelerate your product’s path to market.
As a GMP-certified contract laboratory, we combine deep expertise in solid-state characterization with advanced analytical methods. Our team supports pharmaceutical partners across discovery, clinical development, regulatory submissions, and commercialization, helping transform complex regulatory requirements into actionable data and clear decision-making.
What is bioequivalence?
Bioequivalence refers to the scientific demonstration that two drug products – typically a generic and its reference (innovator) product – show no significant difference in the rate and extent of drug absorption when administered at the same molar dose under similar conditions.
In simple terms, bioequivalence means that the generic drug behaves in the body in the same way as the original, delivering the same therapeutic effect.
Regulators such as the FDA and EMA require comprehensive bioequivalence studies as part of the approval process for generic products. Without proof of bioequivalence, a generic drug cannot be authorized for sale.
Key points of bioequivalence:
- It focuses on drug absorption and bioavailability.
- It is typically assessed using pharmacokinetic endpoints such as Cmax (maximum plasma concentration), Tmax (time to reach Cmax), and AUC (area under the plasma concentration-time curve).
- Bioequivalence ensures that patients can safely switch from a branded drug to its generic equivalent without differences in efficacy or safety.
Bioequivalence requirements
For generic drug development, bioequivalence is one of the most important regulatory requirements. The FDA and EMA mandate that generics must demonstrate therapeutic equivalence through rigorous testing.
FDA guidance on bioequivalence
The FDA guidance on bioequivalence outlines the requirements for different drug formulations, dosage forms, and therapeutic categories. The FDA also publishes product-specific bioequivalence guidance, which provides detailed instructions for demonstrating equivalence in particular products.
EMA requirements
The European Medicines Agency (EMA) requires a similar demonstration of equivalence between generic and reference products. In Europe, regulatory submissions often include both pharmacokinetic and in vitro studies.
ANDA submissions
For generics submitted under an Abbreviated New Drug Application (ANDA), sponsors must conduct bioequivalence studies with pharmacokinetic endpoints to show equivalence with the reference listed drug. Without this data, approval will not be granted.
Particle Analytical’s bioequivalence services
At Particle Analytical, we provide end-to-end bioequivalence services tailored to your development stage and regulatory pathway.
Our services include:
- Solid form studies: Assessing polymorphism, crystallinity, and amorphous content that can impact bioavailability and bioequivalence.
- Particle characterization: Determining particle size distribution and morphology, which affect dissolution and absorption.
- Method development and validation: Creating robust, GMP-compliant analytical methods to support bioequivalence testing.
- Reverse engineering: Comparing your product with reference drugs to understand critical quality attributes.
- Bioequivalence risk assessment: Identifying potential risks to equivalence early in development, reducing costly setbacks.
- Regulatory support: Providing data and documentation for FDA bioequivalence guidance and EMA submissions.
- MDRS bioequivalence studies: Advanced particle analysis in full compliance with FDA recommendations.
By combining regulatory expertise with state-of-the-art instrumentation, we ensure that your bioequivalence package meets the highest quality standards.
Why bioequivalence matters in generic drug development
Bioequivalence studies are not only about satisfying regulators. They are essential for:
- Patient safety and efficacy: Ensuring generic drugs provide the same therapeutic benefits as branded products.
- Market access: Without bioequivalence, generics cannot be launched.
- Cost savings: Demonstrating equivalence avoids unnecessary duplication of clinical trials.
- Trust and reliability: Healthcare providers and patients rely on the proven equivalence of generics.
By outsourcing bioequivalence studies to a specialized laboratory, pharmaceutical companies reduce internal workload, ensure compliance, and gain a reliable partner in navigating complex regulatory landscapes.
Why choose Particle Analytical for bioequivalence studies
With 25 years of experience, our laboratory has developed a reputation for precision, compliance, and dedication to quality.
Choosing the right laboratory partner is critical for successful generic drug development. Particle Analytical stands out because:
GMP-certified contract laboratory
Full compliance with international regulatory standards.
FDA-aligned expertise
Our methods and reporting meet FDA expectations, including ANDA requirements.
Simplified outsourcing
Ship your samples, and we deliver a comprehensive report – saving you time and resources.
Solid-state specialists
Deep knowledge of how crystal form, particle size, and polymorphism affect bioequivalence.
MDRS expertise
Access to FDA-recommended Morphologically-Directed Raman Spectroscopy, enabling advanced in vitro studies.
Proven reliability
Trusted partner for pharmaceutical companies worldwide.
Frequently asked questions about bioequivalence
What does bioequivalence mean?
Bioequivalence means that two drug products show no significant difference in absorption and therapeutic effect when given under the same conditions.
What is the difference between bioavailability and bioequivalence?
Bioavailability refers to the extent and rate at which an active ingredient becomes available in the body.
Bioequivalence compares the bioavailability of two products to ensure they are effectively the same.
What is the difference between bioequivalence and biosimilars?
Bioequivalence applies to generic small-molecule drugs.
Biosimilars are biologic medicines, which require more complex comparability studies, not just bioequivalence testing.
What are FDA bioequivalence requirements?
The FDA requires generics submitted under ANDA to demonstrate bioequivalence to the reference drug. This is done through pharmacokinetic studies, sometimes supported by in vitro testing.
What is product-specific bioequivalence guidance?
The FDA issues product-specific guidance documents that outline the exact requirements for demonstrating equivalence for individual drug products.
What is bioequivalence in pharmacology?
In pharmacology, bioequivalence refers to how two formulations of a drug behave similarly in the body. While widely studied in academia, in the pharmaceutical industry it is primarily applied in the regulatory approval of generics.
What is bioequivalence?
Bioequivalence refers to the scientific demonstration that two drug products – typically a generic and its reference (innovator) product – show no significant difference in the rate and extent of drug absorption when administered at the same molar dose under similar conditions.
In simple terms, bioequivalence means that the generic drug behaves in the body in the same way as the original, delivering the same therapeutic effect.
Regulators such as the FDA and EMA require comprehensive bioequivalence studies as part of the approval process for generic products. Without proof of bioequivalence, a generic drug cannot be authorized for sale.
Key points of bioequivalence:
- It focuses on drug absorption and bioavailability.
- It is typically assessed using pharmacokinetic endpoints such as Cmax (maximum plasma concentration), Tmax (time to reach Cmax), and AUC (area under the plasma concentration-time curve).
- Bioequivalence ensures that patients can safely switch from a branded drug to its generic equivalent without differences in efficacy or safety.
Partner with Particle Analytical
Bioequivalence is more than a regulatory hurdle – it is a guarantee of therapeutic equivalence, patient safety, and market access. At Particle Analytical, we help pharmaceutical companies meet FDA and EMA requirements with confidence.
By outsourcing your bioequivalence studies to our GMP-certified laboratory, you gain:
- A reliable partner specialized in pharmaceutical analysis.
- Data-driven results that support regulatory approval.
- Faster, more cost-effective development timelines.
Request a quote for MDRS bioequivalence studies today or contact us to discuss your specific product requirements. Our experts are ready to support your regulatory and development goals.